Skip to main content
Fig. 3 | BMC Oral Health

Fig. 3

From: Characterization of immunologically detectable T-cell sensitization, Immunohistochemical detection of pro-inflammatory cytokines, and clinical parameters of patients after allogeneic intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans

Fig. 3

a-f Immunohistochemical analysis of IL-1α, IL-1ß and TNF-α. a, b Immunostaining for IL-1α. (A) Weak immunostaining pattern: staining of bone lining cells (arrow), b = newly formed bone, Maxgraft®, patient of group A, DAB, original magnification × 20); (B) Moderate immunostaining: Staining of a cluster of fibroblasts (f), b = newly formed bone, M = Maxgraft® granules, Maxgraft,® patient of group C, DAB, original magnification × 20. c, d Immunostaining for IL-1ß. (A) Weak immunostaining pattern: staining of bone lining cells and vessel walls (arrows), b = newly formed bone, Puros®, patient of group A; DAB, original magnification × 20); (B) Strong immunostaining: stronger extracellular immunoreactivity within connective tissue areas (asterisks), b = newly formed bone, Puros®, patient of group C, DAB, original magnification × 20. e, f Immunostaining for TNF-α. (A) Weak immunostaining pattern: staining of fibroblasts and vessel walls (arrows), b = newly formed bone, M = Maxgraft® granules, patient of group A DAB, original magnification × 10); (B) Strong immunostaining: Extracellular immunoreactivity and fibroblast staining (asterisks) in the connective tissue among Maxgraft® granules (M) with newly formed bone (b), patient of group C DAB, original magnification × 10

Back to article page

BMC Oral Health

ISSN: 1472-6831

Contact us